Document is current

Article History

Received: 12 April 2021

Accepted: 23 June 2021

First Online: 16 July 2021

Declarations

:

: JD declares congress invitations from Sanofi, Eli Lilly, Novo Nordisk, and Roche. MD has no personal disclosures. EH is the Chief of Executive Officer Diabeloop. SF declares congress invitations from Sanofi, Eli Lilly, MSD, Novo Nordisk, Roche, Abbott and Boehringer; she has received speaker honoraria from Lilly, Novo Nordisk and served on advisory board panels for Novo Nordisk, Roche, Diabeloop, Sanofi, Janssen and Lifescan. She owns shares in Diabeloop SA. GC has received congress invitations, honoraria and consultancy fees from Abbott, Dexcom, Medtronic, and owns shares in Diabeloop SA. AV has received speaker honoraria from Eli Lilly, Novo Nordisk, Roche, Abbott, Sanofi, MSD, Lifescan, Ascensia, AstraZeneca and served on advisory board panels for Roche, Diabeloop, Eli Lilly, and AstraZeneca. PYB has received speaker honoraria from Abbott, Roche, Eli Lilly, Novo Nordisk, Sanofi and served on advisory board panels for Abbott, Dexcom, Diabeloop, Insulet, Lifescan, Eli Lilly, Medtronic, Novo Nordisk, Roche, and Sanofi. SL has received speaker honoraria from Abbott, Novo Nordisk, Sanofi, Eli Lilly, Insulet and served on advisory board panels for Diabeloop and Medtronic. CS has no personal disclosures.

: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee (French Committee for the Protection of Persons participating in biomedical research [CPP France-Est III]; CPP: 19-06-08, RCB: 2019-A01365-52, 3 July 2019), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: A signed informed consent was obtained from all individual participants included in this study.